Implantica announces that another prominent anti-reflux center has started operating with implantable medical device RefluxStop™
Implantica AG (publ) today announces that Klinikum Friedrichshafen in Germany, one of the largest anti-reflux centers, has begun implementing RefluxStop™. The hospital has successfully completed several surgeries with RefluxStop™ performed by Prof. Dr. med. Lehmann and his team.
“We welcome the adoption of the RefluxStop™ surgical procedure by another prominent anti-reflux center and renowned surgeon in Germany, and we look forward to working together with Prof. Dr. med. Lehmann. We anticipate more and more centers to begin with RefluxStop™ as the effects of COVID-19 ease.” said Peter Forsell, CEO of Implantica.
For further information, please contact:
Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399, email@example.com
The information was sent for publication, through the agency of the contact person set out above, on July 07, 2021 at 08:30 a.m. CET.
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.